Florent Malard

Oct 24, 2024 | nature.com | Ana Alarcon Tomas |Edouard Forcade |Vladan Vucinic |Nicolaus Kröger |Lucía López Corral |Jan Vydra | +10 more

Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].

Sep 9, 2024 | onlinelibrary.wiley.com | Mohamad Mohty |Hôpital Antoine |Florent Malard

Autologous haematopoietic cell transplantation (auto-HCT) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma (MM) patients. The procedure comprises several key steps: induction, haematopoietic stem cell mobilization, high-dose chemotherapy (melphalan) followed by haematopoietic cell infusion and post-transplant therapy (including maintenance therapy with or without prior consolidation).

Aug 11, 2024 | nature.com | Mohamad Mohty |Florent Malard

AbstractMultiple myeloma (MM) is a chronic hematologic malignancy that remains incurable, because most patients eventually relapse or become refractory to current treatments. MM is a major health problem, with a globally increasing incidence.

Jul 23, 2023 | onlinelibrary.wiley.com | Florent Malard |Hôpital Saint-Antoine |AP-HP Paris France

Abstract Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade.